EP2557923A4 - Traitement de cancers présentant des mutations k-ras - Google Patents

Traitement de cancers présentant des mutations k-ras

Info

Publication number
EP2557923A4
EP2557923A4 EP11769663.3A EP11769663A EP2557923A4 EP 2557923 A4 EP2557923 A4 EP 2557923A4 EP 11769663 A EP11769663 A EP 11769663A EP 2557923 A4 EP2557923 A4 EP 2557923A4
Authority
EP
European Patent Office
Prior art keywords
cancers
treatment
ras mutations
ras
mutations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP11769663.3A
Other languages
German (de)
English (en)
Other versions
EP2557923A1 (fr
Inventor
Rudi Bao
Chengjung Lai
Changgeng Qian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Curis Inc
Original Assignee
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curis Inc filed Critical Curis Inc
Publication of EP2557923A1 publication Critical patent/EP2557923A1/fr
Publication of EP2557923A4 publication Critical patent/EP2557923A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP11769663.3A 2010-04-16 2011-04-15 Traitement de cancers présentant des mutations k-ras Withdrawn EP2557923A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32491210P 2010-04-16 2010-04-16
PCT/US2011/032683 WO2011130628A1 (fr) 2010-04-16 2011-04-15 Traitement de cancers présentant des mutations k-ras

Publications (2)

Publication Number Publication Date
EP2557923A1 EP2557923A1 (fr) 2013-02-20
EP2557923A4 true EP2557923A4 (fr) 2013-10-23

Family

ID=44799046

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11769663.3A Withdrawn EP2557923A4 (fr) 2010-04-16 2011-04-15 Traitement de cancers présentant des mutations k-ras

Country Status (6)

Country Link
EP (1) EP2557923A4 (fr)
JP (1) JP2013525308A (fr)
CN (1) CN102970868A (fr)
AU (1) AU2011239537A1 (fr)
CA (1) CA2795952A1 (fr)
WO (1) WO2011130628A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2074122B9 (fr) * 2006-09-15 2013-09-11 Pfizer Products Inc. Composés de pyrido (2, 3-d) pyrimidin0ne et leur utilisation en tant qu'inhibiteurs de pi3
US8367663B2 (en) 2009-01-08 2013-02-05 Curis, Inc. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety
KR20180108848A (ko) 2011-04-01 2018-10-04 쿠리스 인코퍼레이션 아연 결합 모이어티를 갖는 포스포이노시티드 ３-키나아제 억제제
WO2013078126A1 (fr) 2011-11-23 2013-05-30 Cancer Research Technology Limited Inhibiteurs de type thiénopyrimidine de protéines kinases c atypiques
US8940742B2 (en) * 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6441910B2 (ja) * 2013-09-30 2018-12-19 シャンハイ インリ ファーマシューティカル カンパニー リミティド 縮合ピリミジン化合物、中間体、その調製方法、組成物及び使用
WO2015054099A1 (fr) * 2013-10-08 2015-04-16 Acetylon Pharmaceuticals, Inc. Combinaisons d'inhibiteurs d'histone désacétylase et d'inhibiteurs d'her2 ou de pi3k
CN106163524B (zh) * 2013-11-15 2019-11-08 昂克希尔迪克斯有限公司 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1H)-酮、其盐及应用方法
CN103601745B (zh) * 2013-11-26 2017-01-18 大连联化化学有限公司 一种通用的乙酰氨基吡啶硼酸频哪醇酯的制备方法
CN106456643B (zh) * 2014-03-31 2020-04-17 斯克里普斯研究学院 用于trail诱导的药效团
CN104131034B (zh) * 2014-06-19 2017-04-05 中山大学 一种嵌合载体及其制备方法和应用
MX2017009843A (es) * 2015-01-30 2017-11-02 Basf Se Fenilpirimidinas herbicidas.
US10227347B2 (en) 2015-04-21 2019-03-12 Guizhou Bailing Group Pharmaceutical Co., Ltd. Purinyl-N-hydroxyl pyrimidine formamide derivative, preparation methods and uses thereof
CN105037345B (zh) * 2015-06-09 2019-01-25 天津渤海职业技术学院 抗肿瘤化合物、其制备方法和用途
US9630968B1 (en) 2015-12-23 2017-04-25 Arqule, Inc. Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof
WO2018039310A1 (fr) 2016-08-24 2018-03-01 Arqule, Inc. Composés amino-pyrrolopyrimidinone et leurs procédés d'utilisation
WO2018062382A1 (fr) * 2016-09-29 2018-04-05 第一三共株式会社 Cristaux de [2-(1-méthyl-1h-pyrazol-4-yl)-6-(morpholin-4-yl)-9h-purin-8-yl][4-(morpholin-4-yl)pipéridin-1-yl]méthanone et sel pharmaceutiquement acceptable de celle-ci
WO2019043217A1 (fr) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag Dihydrobenzimidazolones
US11351156B2 (en) 2017-10-13 2022-06-07 Inserm Combination treatment of pancreatic cancer
CA3099148A1 (fr) * 2018-05-10 2019-11-14 The University Of Louisville Research Foundation, Inc. Inhibiteurs de l'oncoproteine ras, leurs procedes de preparation et leurs methodes d'utilisation
BR112021004371A2 (pt) 2018-09-11 2021-05-25 Curis Inc. terapia em combinação com um inibidor de fosfoinositídeo 3-quinase com uma porção de ligação a zinco
WO2020132071A1 (fr) * 2018-12-19 2020-06-25 Shy Therapeutics. Llc Composés interagissant avec la superfamille ras pour le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladie fibrotique
EP3935050B1 (fr) 2019-03-06 2024-10-02 C4 Therapeutics, Inc. Composés hétérocycliques pour traitement médical
US11161852B1 (en) 2020-05-08 2021-11-02 Halia Therapeutics, Inc. Inhibitors of NEK7 kinase
CN115768427A (zh) * 2020-06-04 2023-03-07 皮莱环球有限责任公司 癌症疗法中用于靶向降解不可靶向的kras的新型小分子
CN113735830B (zh) * 2021-10-11 2024-08-20 成都自豪药业有限公司 一类羟肟酸衍生物及其应用
WO2024041519A1 (fr) * 2022-08-24 2024-02-29 上海璎黎药业有限公司 Composé morpholinyl quinazoline, composition pharmaceutique et utilisation associée

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006097449A1 (fr) * 2005-03-15 2006-09-21 Menarini International Operations Luxembourg S.A. N-hydroxyamides omega-substitues par des groupes tricycliques, servant d'inhibiteurs d'histone desacetylase, leur preparation et leur utilisation dans des formulations pharmaceutiques
WO2008076447A2 (fr) * 2006-12-15 2008-06-26 Ordway Research Institute Traitements de maladies résistantes aux thérapies et combinaisons médicamenteuses pour traiter celles-ci
WO2009129335A2 (fr) * 2008-04-15 2009-10-22 Pharmacyclics, Inc. Inhibiteurs sélectifs de l'histone désacétylase
WO2009155659A1 (fr) * 2008-06-27 2009-12-30 The University Of Queensland Polythérapie

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5500990B2 (ja) * 2006-12-07 2014-05-21 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト ホスホイノシチド３−キナーゼ阻害剤化合物及び使用方法
WO2008100985A2 (fr) * 2007-02-15 2008-08-21 Novartis Ag Combinaisons d'agents thérapeutiques pour le traitement du cancer
US8367663B2 (en) * 2009-01-08 2013-02-05 Curis, Inc. Phosphoinositide 3-kinase inhibitors with a zinc binding moiety

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006097449A1 (fr) * 2005-03-15 2006-09-21 Menarini International Operations Luxembourg S.A. N-hydroxyamides omega-substitues par des groupes tricycliques, servant d'inhibiteurs d'histone desacetylase, leur preparation et leur utilisation dans des formulations pharmaceutiques
WO2008076447A2 (fr) * 2006-12-15 2008-06-26 Ordway Research Institute Traitements de maladies résistantes aux thérapies et combinaisons médicamenteuses pour traiter celles-ci
WO2009129335A2 (fr) * 2008-04-15 2009-10-22 Pharmacyclics, Inc. Inhibiteurs sélectifs de l'histone désacétylase
WO2009155659A1 (fr) * 2008-06-27 2009-12-30 The University Of Queensland Polythérapie

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
CHIA-WEI CHOU ET AL: "HDAC Inhibition Decreases the Expression of EGFR in Colorectal Cancer Cells", PLOS ONE, vol. 6, no. 3, 25 March 2011 (2011-03-25), pages e18087, XP055078579, DOI: 10.1371/journal.pone.0018087 *
DENLINGER ET AL: "Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non-small cell lung cancer in vitro and in vivo", JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, MOSBY-YEAR BOOK, INC., ST. LOUIS, MO, US, vol. 130, no. 5, 1 November 2005 (2005-11-01), pages 1422 - 1429, XP005127283, ISSN: 0022-5223, DOI: 10.1016/J.JTCVS.2005.06.051 *
E LOPEZ-CRAPEZ ET AL: "Rapid and large-scale method to detect K-ras gene mutations in tumor samples", CLINICAL CHEMISTRY, 1 January 1997 (1997-01-01), pages 936 - 942, XP055078570, Retrieved from the Internet <URL:http://www.clinchem.org/content/43/6/936.full.pdf+html> [retrieved on 20130910] *
FRANKLIN WILBUR A ET AL: "KRAS Mutation Comparison of Testing Methods and Tissue Sampling Techniques in Colon Cance", JOURNAL OF MOLECULAR DIAGNOSTICS,THE, AMERICAN SOCIETY FOR INVESTIGATIVE PATHOLOGY, US, vol. 12, no. 1, 1 January 2010 (2010-01-01), pages 43 - 50, XP009168344, ISSN: 1525-1578 *
G. J. RIELY ET AL: "KRAS Mutations in Non-Small Cell Lung Cancer", PROCEEDINGS OF THE AMERICAN THORACIC SOCIETY, vol. 6, no. 2, 15 April 2009 (2009-04-15), pages 201 - 205, XP055024772, ISSN: 1546-3222, DOI: 10.1513/pats.200809-107LC *
JEET GANDHI ET AL: "Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines", PLOS ONE, PUBLIC LIBRARY OF SCIENCE, US, vol. 4, no. 2, 24 February 2009 (2009-02-24), pages E4576 - 1, XP002677508, ISSN: 1932-6203, DOI: 10.1371/JOURNAL.PONE.0004576 *
KRYPUY MICHAEL ET AL: "High resolution melting analysis for the rapid and sensitive detection of mutations in clinical samples: KRAS codon 12 and 13 mutations in non-small cell lung cancer", BMC CANCER, BIOMED CENTRAL, LONDON, GB, vol. 6, no. 1, 21 December 2006 (2006-12-21), pages 295, XP021023081, ISSN: 1471-2407, DOI: 10.1186/1471-2407-6-295 *
M A LEA ET AL: "Induction of Differentiation of Colon Cancer Cells by Combined Inhibition of Kinases and Histone Deacetylase", ANTICANCER RESEARCH, vol. 27, 1 January 2007 (2007-01-01), pages 741 - 748, XP055079030 *
N SUNAGA ET AL: "Knockdown of Oncogenic KRAS in Non-Small Cell Lung Cancers Suppresses Tumor Growth and Sensitizes Tumor Cells to Targeted Therapy", MOLECULAR CANCER THERAPEUTICS, vol. 10, 1 January 2011 (2011-01-01), pages 336 - 346, XP055079048 *
PERGOLIZZI ROBERT G ET AL: "Mutational status of codons 12 and 13 of the N- and K-ras genes in tissue and cell lines derived from primary and metastatic prostate carcinomas", CANCER INVESTIGATION, vol. 11, no. 1, 1993, pages 25 - 32, XP008164834, ISSN: 0735-7907 *
REDDY G K: "EARLY CLINICAL DATA AND POTENTIAL CLINICAL UTILITY OF NOVEL HISTONE DEACETYLASE INHIBITORS IN PROSTATE CANCER", CLINICAL PROSTATE CANCER, CANCER INFORMATION GROUP, DALLAS, TX, US, vol. 4, no. 2, 1 January 2005 (2005-01-01), pages 83 - 85, XP009079218, ISSN: 1540-0352 *
See also references of WO2011130628A1 *
WANG QINGDING ET AL: "Augmentation of sodium butyrate-induced apoptosis by phosphatidylinositol 3'-kinase inhibition in the KM20 human colon cancer cell line.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH JUN 2002, vol. 8, no. 6, June 2002 (2002-06-01), pages 1940 - 1947, XP055079069, ISSN: 1078-0432 *
YU X-D ET AL: "Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells", CANCER JOURNAL, JONES AND BARTLETT PUBLISHERS, US, vol. 13, no. 2, 1 March 2007 (2007-03-01), pages 105 - 113, XP008111377, ISSN: 1528-9117 *

Also Published As

Publication number Publication date
JP2013525308A (ja) 2013-06-20
CA2795952A1 (fr) 2011-10-20
CN102970868A (zh) 2013-03-13
EP2557923A1 (fr) 2013-02-20
AU2011239537A1 (en) 2012-11-15
WO2011130628A1 (fr) 2011-10-20

Similar Documents

Publication Publication Date Title
EP2557923A4 (fr) Traitement de cancers présentant des mutations k-ras
IL276362A (en) Cancer treatment methods
SG10201508495VA (en) Combination treatment of cancer
HK1202253A1 (en) Combination treatment of cancer
IL218575A0 (en) Treatment of cancer
HRP20170225T1 (hr) Fosfoplatini i njihova uporaba za liječenje karcinoma
HK1189272A1 (zh) 治療癌症的方法
EP2506875A4 (fr) Procédés et traitement de cancers comprenant des mutations k-ras
EP2640390A4 (fr) Procédés de traitement du cancer
PL388252A1 (pl) Terapia skojarzona raka jelita grubego
GB0916686D0 (en) Treatment of cancer
GB201017356D0 (en) Combination treatment of cancer
GB201017354D0 (en) Treatment of cancer
GB201002499D0 (en) Treatment of tumours
GB201121791D0 (en) Combination treatment of cancer
GB0921757D0 (en) Treatment of cancer
GB201301168D0 (en) Cancer treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20121115

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1179472

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20130924

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/19 20060101ALI20130918BHEP

Ipc: A61K 45/06 20060101ALI20130918BHEP

Ipc: A61K 31/167 20060101AFI20130918BHEP

Ipc: A61K 31/496 20060101ALI20130918BHEP

Ipc: A61K 31/4985 20060101ALI20130918BHEP

Ipc: A61K 31/16 20060101ALI20130918BHEP

Ipc: A61P 35/00 20060101ALI20130918BHEP

Ipc: A61K 31/38 20060101ALI20130918BHEP

Ipc: A61K 31/5355 20060101ALI20130918BHEP

Ipc: A61K 31/343 20060101ALI20130918BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20140423

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1179472

Country of ref document: HK